Core Viewpoint - The report from CMB International highlights that 3SBio's partner has significantly accelerated the overseas clinical development of SSGJ-707 (PF-4404), with Pfizer recently disclosing plans to focus on speed, breadth, and depth in its development [1] Group 1: Clinical Development - 3SBio's partner has accelerated the overseas clinical development of SSGJ-707 (PF-4404) [1] - Pfizer's recent disclosure indicates a strategic focus on enhancing the speed, breadth, and depth of the drug's development [1] Group 2: Business Strategy - 3SBio announced plans to spin off its consumer pharmaceutical business, Mandi International, for a listing on the Hong Kong Stock Exchange [1] - Post-spin-off, 3SBio will no longer hold any equity in Mandi International, which is expected to generate short-term investment returns and allow the company to focus on its core prescription and innovative drug business [1] Group 3: Financial Outlook - CMB International has raised its target price for 3SBio to HKD 39.5 and maintains a "Buy" rating along with a sector focus recommendation [1]

Group 1 - Pfizer has accelerated the development of SSGJ-707 (PF-4404) with plans to initiate at least 7 clinical trials, including two global Phase III trials starting in December targeting 1L sq-/nsq-NSCLC and metastatic colorectal cancer [1] - The company aims to expand SSGJ-707 into over 10 new indications and more than 10 new combination therapies by the end of 2026, including evaluating its use with Pfizer's extensive ADC product portfolio [1] - Pfizer has identified over 500 clinical centers across more than 25 countries for the development of PF-4404 and has completed domestic production in the U.S. to ensure efficient development and compliance with global registration requirements [1] Group 2 - The company plans to spin off its consumer pharmaceutical business, Mandi International, for a listing on the Hong Kong Stock Exchange, which will allow it to focus on prescription and innovative drugs [2] - The spin-off is expected to generate short-term investment returns and support the commercialization of new products after the separation [2] - The target price for the stock has been raised to 39.5 HKD due to strong clinical data and partner support, reflecting increased confidence in the global development of SSGJ-707 [2]

Core Viewpoint - Guosen Securities maintains an "outperform" rating for 3SBio (01530), highlighting the rapid global clinical development of its core products and robust performance growth, particularly following the successful licensing of 707 [1] Group 1: Clinical Development - 3SBio presented Phase 2 clinical data for 707 in combination with chemotherapy for 1L NSCLC at the STIC conference, showing good efficacy and safety in both sqNSCLC and nsqNSCLC, supporting further Phase 3 studies [1] - Pfizer discussed the global clinical strategy for 707, focusing on two key Phase 3 trials for NSCLC 1L and mCRC 1L, with plans to initiate five additional studies soon [1] Group 2: Financial Projections - Guosen Securities raised its profit forecast for 3SBio, expecting net profit attributable to shareholders to reach 9.955 billion, 2.875 billion, and 3.212 billion yuan for 2025-2027, up from previous estimates of 2.38 billion, 2.71 billion, and 3.07 billion yuan [1] Group 3: Future Development Plans - Pfizer's second wave of development plans aims to add 10 new indications and over 10 novel combination therapies by the end of 2026, targeting to replace existing standard treatments with 707 [1] - The strategy includes exploring combinations with ADCs and developing non-chemotherapy options, expanding applications to early treatment scenarios [1]

Core Viewpoint - Guosen Securities maintains an "outperform" rating for 3SBio (01530), highlighting the rapid global clinical development of its core products and robust performance growth, particularly following the successful licensing of 707. The profit forecast for 2025-2027 has been raised, with expected net profits of 9.955 billion, 2.875 billion, and 3.212 billion yuan respectively, up from previous estimates of 2.38 billion, 2.71 billion, and 3.07 billion yuan [1]. Group 1 - 3SBio presented clinical phase II data for 707 in combination with chemotherapy for 1L NSCLC at the STIC conference, demonstrating good efficacy and safety in both sqNSCLC and nsqNSCLC, supporting the continuation of phase III trials [1]. - Pfizer discussed the global clinical strategy for 707, focusing on two key phase III trials for NSCLC1L and mCRC1L, with plans to initiate five additional studies soon, including phase 2/3 for ES-SCLC1L and phase 1/2 for various other indications [1]. - Pfizer's second wave of development plans aims to add 10 new indications and over 10 novel combination regimens by the end of 2026, targeting the replacement of existing standard treatments with 707 as a new cornerstone therapy [1].

Core Insights - The price war in the vaccine industry is driven by changes in supply and demand dynamics, leading to significant price reductions and financial losses for companies [2][10][15] Group 1: Price Trends - The price of a three-valent flu vaccine has dropped to 5.5 yuan, lower than the price of a cup of milk tea, indicating a drastic reduction in vaccine prices [3][7] - The price of the four-valent flu vaccine has decreased from 128 yuan to 88 yuan, with further reductions expected as competition intensifies [7][8] - HPV vaccines have also seen significant price drops, with the two-valent HPV vaccine priced at 27.5 yuan, down over 90% from previous prices [8] Group 2: Industry Response - The China Vaccine Industry Association issued an initiative to combat "involutionary" competition, urging members to avoid bidding below cost and maintain price stability [4][5] - The association's initiative aims to stabilize price expectations but may not address the underlying issue of overcapacity in the industry [3][10] Group 3: Market Dynamics - The vaccine market is experiencing overcapacity due to an influx of companies entering the sector, leading to intense competition and price wars [10][11] - Demand for vaccines is under pressure, with declining public trust in vaccines and a decrease in birth rates affecting the market for childhood vaccines [11][12] Group 4: Financial Impact - Vaccine companies have reported significant financial losses, with overall revenue for listed vaccine companies dropping by 60% and net profits declining by 113% in the first half of 2025 [12][14] - Major companies like Zhifei Biological and Wantai Biological have reported substantial revenue declines and net losses, reflecting the severe impact of the price war [12][14] Group 5: Future Outlook - Experts suggest that the industry may need to undergo a period of consolidation and restructuring, which could last five to ten years, to address the current challenges [15] - Companies are exploring international markets and differentiation strategies to navigate the competitive landscape, with some reporting significant increases in exports [15]

Market Performance - On November 26, the Shenzhen Component Index and the ChiNext Index opened low but closed higher, with the ChiNext Index rising over 3% at one point. The Shanghai Composite Index fell by 0.15%, while the Shenzhen Component Index increased by 1.02% and the ChiNext Index rose by 2.14% [2] - Over 3,500 stocks in the market declined, with a total trading volume of 1.78 trillion yuan, a decrease of 28.8 billion yuan compared to the previous trading day [2] Sector Performance - The pharmaceutical, retail, and CPO sectors saw significant gains, while military equipment, forestry, and gaming sectors experienced notable declines [2] - The pharmaceutical sector showed strong performance, with various sub-sectors such as pharmaceutical commerce and e-commerce rising significantly [8][9] Capital Flow - There was a notable inflow of capital into the CPO sector, with over 142 billion yuan net inflow into the telecommunications industry, leading the primary industry sectors. By the end of the day, there was an additional net inflow of over 164 billion yuan [2] - The "Yizhongtian" stocks, including Zhongji Xuchuang, saw significant gains, with Zhongji Xuchuang reaching a historical high [2][3] AI and Technology Sector Outlook - The AI computing power industry is experiencing high demand, with expectations for increased capital expenditure from leading cloud vendors. The industry is transitioning from 800G to 1.6T technology, benefiting optical module manufacturers [7] - The rise of large models and generative AI applications is expected to expand the market for AI servers, driving rapid growth in demand for high-speed optical modules [7] Currency Impact - The offshore and onshore RMB against the USD both broke the 7.09 mark, reaching a new high in over a year, which is expected to enhance the attractiveness of RMB assets and positively impact the A-share market [11]

Core Viewpoint - Recently, 3SBio announced the proposal to spin off its subsidiary Mandi International for independent listing on the Hong Kong Stock Exchange, with 3SBio holding 87.16% of Mandi's shares, and after the spin-off, 3SBio will not retain any interests in Mandi [1][5] Group 1: Company Overview - Mandi International was established in 1997 as Zhejiang Wansheng Pharmaceutical Co., Ltd., and launched China's first 5% minoxidil product in 2001, filling a gap in the domestic hair loss treatment market [1][2] - Mandi International's revenue is primarily dependent on the Mandi product series, which includes 5% minoxidil solutions and shampoos, contributing over 90% of its revenue [3][4] Group 2: Market Potential - The hair health management market in China has expanded from 19.8 billion yuan in 2018 to an estimated 52.7 billion yuan in 2024, with a projected compound annual growth rate (CAGR) of 11.3% from 2024 to 2035 [2] - Over 339 million people in China are affected by hair loss, with more than 60% of them under the age of 35 [2] Group 3: Financial Performance - Mandi International's revenue from 2022 to 2024 is projected to grow from 982 million yuan to 1.455 billion yuan, with a CAGR of 21.7%, and net profits are expected to rise from 202 million yuan to 390 million yuan [3] - In the first half of 2025, Mandi International achieved revenue of 743 million yuan, a year-on-year increase of approximately 20.2% [3] Group 4: Product Development - Mandi International launched the second-generation minoxidil product, Mandi 5% minoxidil foam, which saw rapid sales growth, generating 307 million yuan in 2024 and 283 million yuan in the first half of 2025 [4] - The company has a pipeline of products under development, including treatments for acne, obesity, and vitiligo, although these contribute less to current revenue [4] Group 5: Strategic Rationale for Spin-off - The spin-off is expected to provide multiple commercial benefits, including enhanced value transparency, independent financing platforms, and optimized management responsibilities, which will improve decision-making and market responsiveness [5]

Core Viewpoint - Pfizer has successfully completed the acquisition of Metsera for approximately $9.2 billion, gaining access to key assets MET-097i and MET-233i, indicating a strategic move in the long-acting weight loss and diabetes treatment market [1] Company Developments - The stock price of Gilead Sciences-B (01672) has increased by 6.25%, reaching HKD 14.46, with a trading volume of HKD 39.59 million [1] - Gilead has developed a subcutaneous reservoir technology platform (ULAP) for long-acting weight loss drugs, positioning itself in the competitive landscape of obesity and diabetes treatments [1] Industry Trends - Eli Lilly and Novo Nordisk are also actively pursuing long-acting platforms, having formed strategic partnerships with Camurus and Ascendis to develop long-acting weight loss and diabetes products by 2025 [1] - Open Source Securities predicts that the value of long-acting pipelines and technology platforms will become more apparent as clinical data is disclosed, suggesting that long-acting therapies will be a key differentiator in the weight loss and diabetes treatment market [1] - Various technologies such as antibody-drug conjugates, fatty acid end-modification, and subcutaneous reservoir sustained-release methods are expected to enable long-acting drug delivery [1]

Investment Rating - The report assigns a "Buy" rating to several companies in the pharmaceutical sector, indicating a potential upside of over 15% in the next 12 months [2][30]. Core Insights - The MSCI China Healthcare Index has increased by 62.8% from early 2025, outperforming the MSCI China Index by 32.2%. However, there has been a recent pullback of 8% in the healthcare sector since October [1]. - The report highlights a resurgence in the demand for domestic innovative drug research and development, driven by a recovery in capital market financing and an increase in overseas transactions for innovative drugs [1][3]. - Major multinational corporations (MNCs) are actively pursuing acquisitions in the pharmaceutical sector, with significant transactions indicating strong motivation to acquire quality assets [3]. - The report emphasizes the importance of clinical advancements in authorized innovative drug pipelines overseas as key catalysts for the sector [3]. Summary by Sections Section: Investment Opportunities - The report recommends buying shares of companies such as 三生制药 (Sangfor), 固生堂 (Gushengtang), 药明合联 (WuXi AppTec), 巨子生物 (Giant Biologics), 信达生物 (Innovent Biologics), and 中国生物制药 (China National Pharmaceutical Group) due to their attractive valuations and growth potential [2][3]. Section: Market Trends - The report notes that from January to October 2025, China's innovative drug overseas transaction amounts accounted for 38% of the global total, with upfront payments making up 50%, significantly higher than the figures from 2020 [3]. - The report also points out that the pressure on medical insurance revenue and expenditure remains, with a 4.6% year-on-year increase in income and a 1.7% decrease in expenditure from January to September 2025 [3]. Section: Clinical Development - The report highlights that Pfizer is set to initiate seven clinical trials related to its PD-1/VEGF drug candidate, which will cover over ten indications and innovative combination therapies by 2026 [3].

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology industry, specifically recommending stocks such as Yifeng Pharmacy and Dazhenglin [1]. Core Insights - The report highlights that the cash flow of pharmacies is stable and valuations are low, indicating potential investment opportunities in leading pharmacy chains [1]. - The A-share pharmaceutical index has shown a year-to-date increase of 13.7%, while the Hang Seng Biotechnology Index has surged by 74.2% [4]. - The report identifies a turning point in the pharmacy industry, with a net decrease of 4,000 pharmacies in Q4 2024, suggesting a shift to a stock competition phase [4][24]. - The report emphasizes the importance of cost reduction and efficiency improvements among leading pharmacy chains, which have resulted in improved profit margins [27]. Summary by Sections Industry Trends - The A-share pharmaceutical index has decreased by 6.9% this week, with significant declines across various sub-sectors, including medical devices and traditional Chinese medicine [4][9]. - Leading pharmacy chains are focusing on store adjustments and have shown marginal performance improvements, with revenue growth of 0.6% and net profit growth of 12.4% in the first three quarters of 2025 [20]. Valuation and Performance - As of November 23, 2025, the SW pharmacy sector's PE-TTM is approximately 21.5 times, indicating a valuation at the 37th percentile for the year [22]. - Major pharmacy chains like Yifeng Pharmacy and Dazhenglin have PEs below 20 times, highlighting their attractive valuation [22]. Research and Development Progress - The report details recent approvals and clinical advancements in innovative drugs, including the approval of Pfizer's long-acting hemophilia treatment [4]. - Specific recommendations for innovative drugs include companies such as Baidu Tianheng and BeiGene, with a focus on PD1/VEGF dual antibodies and GLP1 drugs [9][11][12]. Market Dynamics - The report notes that the number of retail pharmacies has begun to decline, marking a significant shift in the market landscape [24]. - Leading pharmacy chains are expected to enhance their market share through refined management and compliance capabilities [24].